Egg donation is a multi-step medical process that typically spans four to six weeks from initial screening through egg retrieval. It involves medical and psychological evaluations, a course of injectable hormone medications to stimulate the ovaries, regular monitoring appointments, and a short surgical procedure to collect the eggs. The process is more involved than many people expect, and the specifics at each stage matter for both your comfort and safety.
Screening and Medical Evaluation
Before any medication enters the picture, you go through a thorough screening process. Clinics evaluate your medical history, family history, and reproductive health. Blood tests check hormone levels, and one of the most important markers is anti-Müllerian hormone (AMH), which gives the medical team a sense of your ovarian reserve. Research on egg donor populations has found that women with higher AMH levels tend to produce more eggs during stimulation, and that the number of eggs retrieved decreases with age. One study identified an AMH cutoff of about 1.12 ng/mL as a threshold for successful donation.1PubMed Central. Female Reproductive Health – study of an egg donor population You will also have a transvaginal ultrasound to count antral follicles, the small fluid-filled sacs in the ovaries that each contain an immature egg.
Genetic screening is another piece. Some programs go beyond the baseline guidelines set by professional societies and add tests for conditions like Tay-Sachs disease, Fragile X syndrome, and chromosomal analysis (karyotyping).2Human Reproduction. Evaluating the necessity for universal screening of prospective oocyte donors using enhanced genetic and psychological testing The extent of genetic testing varies from clinic to clinic, and some agencies require more panels than others. Psychological screening is also standard. Many programs use formal psychological assessments alongside interviews with a mental health professional to evaluate your motivations, your understanding of the process, and your emotional readiness for donating genetic material to another family.
Ovarian Stimulation
Once you clear screening, the active medical phase begins. In a normal menstrual cycle, your body selects one dominant follicle and releases a single egg. The goal of ovarian stimulation is to coax multiple follicles to mature at the same time so the clinic can retrieve several eggs in one procedure. This is done with daily injections of gonadotropins, hormones that directly stimulate the ovaries. You typically self-administer these shots into your abdomen or thigh for about 8 to 14 days.
Several stimulation protocols exist, and which one a clinic uses depends on their preference and your individual profile. A systematic review of ovarian stimulation for oocyte donation found that while multiple randomized trials have compared different types of gonadotropins, there is enough variation among them that no single protocol has emerged as clearly superior for all donors.3Human Reproduction Update. Ovarian stimulation for oocyte donation: a systematic review and meta-analysis Alongside the stimulating hormones, you take a second medication to prevent your body from ovulating too early and releasing the eggs before they can be collected. This is commonly either a GnRH antagonist (started a few days into stimulation) or a progestin taken orally.
One area of active research involves “random-start” protocols, which allow stimulation to begin at any point in your menstrual cycle rather than waiting for the start of your period. A multicenter pilot trial tested random-start progestin-primed stimulation in oocyte donors, assigning them to begin during one of five different cycle phases, from early follicular through the luteal phase.4PubMed Central. Feasibility and efficacy of random-start progestin-primed ovarian stimulation: a multicenter pilot randomized controlled trial in oocyte donation This kind of flexibility could make scheduling more convenient for donors in the future, though conventional cycle-start protocols remain the norm at most clinics.
Monitoring During Stimulation
During those 8 to 14 days of injections, you visit the clinic every two to three days for monitoring. Each visit involves a transvaginal ultrasound to measure how many follicles are growing and how large they are, along with blood draws to track hormone levels, particularly estradiol.5PubMed Central. Impact of relative estradiol changes during ovarian stimulation on blastocyst formation and live birth in assisted reproductive technology The medical team uses this information to adjust your medication doses. If your ovaries are responding too aggressively, they may lower the dose; if the response is sluggish, they may increase it. This close surveillance is also how doctors catch early warning signs of ovarian hyperstimulation syndrome, a risk discussed later in this article.
Most donors find the monitoring appointments manageable but time-consuming. Depending on the clinic’s hours and your work schedule, fitting in several morning appointments over two weeks can require some planning. The injections themselves are subcutaneous (just under the skin with a small needle), and while many donors describe mild discomfort, bloating, and mood changes during stimulation, the side effects are usually tolerable.
The Trigger Shot and Its Timing
When the monitoring ultrasound shows that enough follicles have reached an adequate size, the clinic schedules the “trigger shot,” a precisely timed injection that signals the eggs to undergo their final maturation before retrieval. The timing is critical. Egg retrieval is typically scheduled 34 to 40 hours after the trigger, and the specific agent used for the trigger affects the optimal window.6PubMed Central. Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use
Two main trigger options exist. Human chorionic gonadotropin (hCG) is the traditional choice and remains the most widely used. The alternative is a GnRH agonist trigger, which has gained popularity in egg donation specifically because it virtually eliminates the risk of severe ovarian hyperstimulation syndrome.7PubMed Central. The Trigger in IVF Cycles: Molecular Pathways and Clinical Implications A randomized trial comparing the two triggers in oocyte donation cycles found that the number of eggs retrieved and the proportion of mature eggs were comparable between groups, but the hCG group saw nine cases of mild and one case of severe hyperstimulation, while the GnRH agonist group had none.8PubMed. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial Because donors are undergoing this procedure for someone else’s benefit, many clinics now prefer the GnRH agonist trigger to minimize risk to the donor.
The Egg Retrieval Procedure
Retrieval itself is a short surgical procedure, usually lasting 15 to 30 minutes, performed under sedation or light anesthesia. You won’t need to go under general anesthesia in most cases. A physician uses a transvaginal ultrasound probe fitted with a needle guide. The needle passes through the vaginal wall and into each ovarian follicle, and the fluid containing the egg is aspirated (suctioned out).9PubMed. Transvaginal sonographically controlled follicle puncture for oocyte retrieval
Good technique matters. Published recommendations for oocyte retrieval emphasize positioning the ultrasound transducer so that the ovary sits right against the vaginal wall, with no bowel loops in the needle’s path. External abdominal pressure from an assistant can help stabilize the ovary and bring follicles closer, reducing the need for multiple punctures.10Human Reproduction Open. Recommendations for good practice in ultrasound: oocyte pick up Each follicle is drained individually, and the embryology team in the adjacent lab examines the fluid under a microscope to identify and isolate the eggs in real time.
Recovery and Short-Term Risks
After retrieval, you rest at the clinic for one to two hours while the sedation wears off. Most donors go home the same day with instructions to take it easy for 24 to 48 hours. A prospective study of more than 1,000 oocyte retrievals found that while most patients tolerated the procedure well, about 3% experienced severe to very severe pain afterward, and about 2% were still dealing with significant pain two days later. Vaginal bleeding occurred in roughly 3% of procedures, though no cases of internal abdominal bleeding were recorded in that study. Pain tended to increase with the number of eggs retrieved, and about 0.7% of patients required hospitalization for pain management.11Human Reproduction. Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval: prospective study of >1000 oocyte retrievals
Serious surgical complications are uncommon but not zero. A review of over 4,000 oocyte donor cycles found retrieval-related complications in about 0.4% of cases, including internal bleeding, severe pain, and one case of ovarian torsion. About 0.35% of donors in that study were hospitalized, and roughly 0.15% required surgical intervention.12PubMed. Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles These numbers are reassuring in the aggregate, but they underscore that egg retrieval is a real medical procedure with real, if small, surgical risks.
Ovarian Hyperstimulation Syndrome
The most talked-about risk of egg donation is ovarian hyperstimulation syndrome (OHSS), a condition where the ovaries overreact to the stimulation medications. At its core, OHSS involves increased permeability of blood vessels, causing fluid to leak out of the bloodstream and accumulate in the abdomen and, in severe cases, around the lungs. Known risk factors include younger age, low body mass index, polycystic ovarian syndrome, a high antral follicle count, rapidly rising estradiol levels, and a large number of eggs retrieved.13PubMed Central. Ovarian Hyperstimulation Syndrome: Current Views on Pathophysiology, Risk Factors, Prevention, and Management Many of these characteristics are common in egg donors, who tend to be young and have robust ovarian reserve, which is partly why OHSS deserves special attention in this population.
Mild OHSS involves bloating, abdominal discomfort, and nausea that resolve on their own within a few days. Moderate to severe cases can involve significant fluid accumulation, difficulty breathing, blood clots, and, in rare instances, life-threatening complications. The choice of trigger medication makes a substantial difference here. Research on donor self-reports found that GnRH agonist triggers were associated with significantly reduced OHSS symptoms compared to hCG or dual triggers.14PubMed Central. Egg donor self-reports of ovarian hyperstimulation syndrome: severity by trigger type, oocytes retrieved, and prior history The same study found that a donor’s OHSS experience during a first donation cycle was highly predictive of what happened in subsequent cycles, with about 71% of repeat donors reporting the same severity the second time around. If you had significant OHSS symptoms in one cycle, you are likely to again, which is worth factoring into any decision about repeat donations.
What Happens to the Eggs in the Lab
Once eggs are retrieved, the embryology lab takes over. Mature eggs are identified and either fertilized immediately with the recipient’s partner’s or donor’s sperm (in a fresh cycle) or cryopreserved for later use. Egg freezing relies on a technique called vitrification, an ultra-rapid freezing process that prevents ice crystals from forming inside the cell. Recent advances in vitrification have substantially improved egg survival rates and the pregnancy outcomes achieved from frozen eggs.15PubMed Central. Oocyte vitrification: advances, progress and future goals
The growth of egg banking, where eggs are frozen and stored for future recipients, has changed the landscape of egg donation. It means donors and recipients no longer need to synchronize their cycles, which simplifies logistics. However, outcomes from frozen donor eggs are somewhat lower than from fresh ones. A large analysis of U.S. data found live birth rates of about 56% per transfer with fresh donor oocytes compared to about 50% with cryopreserved ones when fresh embryos were transferred.16PubMed. Fresh embryo transfer after in vitro insemination of fresh vs. cryopreserved anonymous donor oocytes A separate study looking at national trends confirmed this gap, with fresh donor oocyte cycles outperforming frozen ones across both fresh and frozen embryo transfers.17PubMed Central. Trends and Outcomes of Fresh and Frozen Donor Oocyte Cycles in the United States The difference is narrowing as freezing technology improves, but it still influences how some recipients and clinics make decisions.
Long-Term Health Considerations for Donors
A question many potential donors have, and one that researchers have spent decades trying to answer, is whether the hormonal stimulation used in egg donation raises long-term cancer risk. The concern is intuitive: you are flooding your ovaries with hormones, so could that promote cancerous changes down the road? The evidence, while imperfect, is broadly reassuring. A comprehensive review found that most studies show fertility treatments do not increase the risks of invasive ovarian cancer, melanoma, or cancers of the breast, uterus, cervix, thyroid, or colon.18PubMed Central. Use of fertility medications and cancer risk: A review and update There is limited evidence of a modest increase in borderline ovarian tumors, a type of low-malignant-potential growth with a favorable prognosis, but the absolute risk is small.
The research has real limitations, though. Most studies are observational, involve relatively small sample sizes, and have followed participants for varying lengths of time. An earlier review noted that while initial studies raised alarm about ovulation-stimulating drugs and ovarian cancer, subsequent work has been “mainly reassuring,” though possible risk increases have been suggested among specific subgroups, particularly women who never became pregnant and those with extensive follow-up periods.19Reproductive BioMedicine Online. Long-term effects of ovulation-stimulating drugs on cancer risk A complicating factor is that infertility itself is associated with higher rates of certain cancers, which makes it difficult to separate the effects of the drugs from the effects of the underlying condition. Egg donors, who are typically fertile, represent a different population than the infertile women in most of these studies, and donor-specific long-term data remain sparse. This is an area where the science is still catching up to the practice.
The Psychological Experience
Psychological screening before donation is not just a formality. The process involves creating genetic offspring that you will have no parental relationship with, and clinics want to ensure you have genuinely thought through what that means. Most donors report positive experiences. A systematic review of psychosocial attitudes and well-being among oocyte donors found results that were “reassuring throughout all donor groups.”20Human Reproduction Update. Investigating psychosocial attitudes, motivations and experiences of oocyte donors, recipients and egg sharers: a systematic review
A study that surveyed donors about their retrospective evaluations found that most reported satisfaction with their experience, and that the psychological difficulties they had anticipated beforehand turned out to be worse than what they actually experienced.21PubMed. Looking back: egg donors’ retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle That said, a minority of donors in the same study reported lingering physical or psychological concerns they attributed to the donation. The takeaway is not that the process is emotionally trivial but that serious negative psychological outcomes are uncommon. Donors whose motivations are primarily altruistic tend to report the highest satisfaction, while those motivated solely by financial compensation sometimes express more ambivalence afterward.
Compensation and Ethical Tensions
In the United States, egg donors are typically compensated between $5,000 and $10,000 per cycle, though amounts vary widely depending on the agency, the donor’s profile, and geographic location. Some agencies advertise significantly higher fees for donors with specific traits, which is where the ethical debate gets sharper. Professional guidelines from the American Society for Reproductive Medicine have historically cautioned against compensation so high that it could be considered coercive, though enforcement is voluntary. On a global scale, most countries with laws governing oocyte donation have made financial compensation illegal, on the basis that monetary reward risks exploiting donors and treating eggs and resulting children as commodities.22Dove Medical Press. Egg donation compensation: ethical and legal challenges
This creates a patchwork of international norms. In some countries, only altruistic donation (with reimbursement for expenses but no profit) is permitted. In others, like Spain, donors receive modest fixed compensation. In the U.S., the largely unregulated market allows wide variation. The ethical questions are genuine: compensation makes donation accessible to a broader range of donors and supports the people willing to undergo a demanding medical process, but it also raises concerns about who ends up donating and whether fully informed consent can coexist with strong financial incentives.
How Genetic Testing Is Reshaping Donor Anonymity
For decades, most egg donation in the U.S. was anonymous. Donors were assured their identity would remain confidential, and recipients chose donors based on profiles without identifying information. Direct-to-consumer genetic testing has fundamentally disrupted this arrangement. Services that allow people to upload their DNA and find biological relatives have made it possible for donor-conceived individuals to identify their genetic donors regardless of any anonymity agreements in place.23Family Court Review. Establishing Identity: How Direct‐to‐Consumer Genetic Testing Challenges the Assumption of Donor Anonymity
This has practical implications if you are considering donation. Even if you choose an anonymous arrangement, there is a realistic chance that a person conceived from your eggs could find you through genetic databases years or decades from now. Many donor-conceived people, recipient parents, and donors are already sharing genetic information in large online communities. Some countries have responded by moving toward mandatory donor registries that allow donor-conceived individuals to access identifying information about their donors once they reach adulthood. If the possibility of future contact matters to you, it is worth understanding that anonymity in egg donation is increasingly a legal fiction rather than a practical reality. Clinics and agencies are beginning to counsel donors accordingly, but the legal frameworks in many jurisdictions have not caught up to the technology.